Treatment of neurodegenerative conditions by disruption of Rhes
AssigneeThe Regents of the University of California
InventorsKenneth Kosik, Israel Hernandez
Life of this patent
Estimating the term…
Abstract
The invention is directed to the treatment of tauopathic neurodegenerative conditions and the underlying processes thereof. Based on the discovery that Rhes acts as a negative regulator of normal tau clearance, the compositions and methods of the invention may be applied to inhibit Rhes and reduce pathogenic tau aggregation. Rhes may be disrupted by disrupting RAS2D gene expression or reducing the abundance of Rhes protein in neurons. Additionally, post-translational modifications of Rhes may be targeted, including the disruption of Rhes farnesylation by the administration of farnesyltransferase inhibitors.
Claims2
A method of treating a tauopathy in a subject, comprising
- administering to the subject a pharmaceutical composition comprising a farnesyltransferase inhibitor;
- wherein the tauopathy is selected from the group consisting of corticobasal degeneration, argyrophilic grain disease, chronic traumatic encephalopathy, Niemann-Pick-C, Guam-AL S-Parkinson's-dementia, post-encephalitic Parkinson's disease, Subacute sclerosing panencephalitis, and progressive supranuclear palsy.
Dependencies are inferred from the claim text.